GlaxoSmithKline tops the list of companies making drugs accessible to poor countries

Jack, Andrew
June 2008
BMJ: British Medical Journal (International Edition);6/21/2008, Vol. 336 Issue 7658, p1396
Academic Journal
The author reports on actions taken by drug manufacturers in Europe in assisting poor countries throughout the world in purchasing medicine. Actions taken by several companies in assisting countries in the developing world are mentioned, including GlaxoSmithKline. Comparisons are made between the efforts made by European and American companies in assisting poor countries in affording medicine. The opinions of Wim Leereveld, the founder of the foundation the Access to Medicines Index, regarding the differences in actions taken by European and American companies in assisting poor countries are mentioned.


Related Articles

  • Study examines access to Rxs.  // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p72 

    The article informs about the Access to Medicine Index, an independent initiative exploring efforts of pharmaceutical companies in developing countries that lack reliable access to medicines, in which GlaxoSmithKline PLC secured first ranking for 2012.

  • Big Pharma has a heart after all.  // New Scientist;2/21/2009, Vol. 201 Issue 2696, p6 

    This article states that GlaxoSmithKline (GSK) has announced a host of measures to make medicines more available to the world's poor, raising hopes that its rivals will do the same. In a speech at Harvard Medical School on 13 February, the chairman of GSK, Andrew Witty, declared that his company...

  • Drug patent plan gets mixed reviews. Butler, Declan // Nature;2/26/2009, Vol. 457 Issue 7233, p1 

    The article discusses the reaction to U.S. pharmaceutical company GlaxoSmithKline's (GSK) decision to share some of its patents to increase research efforts into neglected diseases and make its drugs available to the poorest countries through cheaper prices. Topics include an explanation of a...

  • Say One Thing, Do Another.  // Pharmaceutical Executive;Aug2001, Vol. 21 Issue 8, p26 

    Presents the issues concerning access to medicine in developing countries which were discussed in the annual meeting of the European Federation of Pharmaceutical Industries Association in 2001. Factors which bar access to medicines; Contribution of GlaxoSmithKline company in the improvement of...

  • Time for Cooperation in Health Economics among the Modelling Community. RenĂ©e J.G. Arnold; Ekins, Sean // PharmacoEconomics;2010, Vol. 28 Issue 8, p609 

    In this article the authors discuss the increased use of computational models in tackling health economic and comparative effectiveness questions. The authors reveal that recent studies in the field of pharmacoeconomics show that modelling is being used in determining therapy/market...

  • Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Darba, Josep // PharmacoEconomics;2003, Vol. 21 Issue 16, p1211 

    Discusses about the increase in real expenditure of pharmaceutical companies on drugs in Spain since 1997. Several cost-containment measures taken by Spanish government to keep pharmaceutical expenditures under control; Factors contributed to an increase in the real expenditure of pharmaceutical...

  • US trade agreement threatens to increase drug prices and withhold safety data. Cohen, Deborah // BMJ: British Medical Journal;11/23/2013, Vol. 347 Issue 7934, p1 

    The article reports on the criticism by campaign groups on the U.S. government for bullying drug companies during trade negotiations with Asian and Latin American countries in 2013.

  • TRANS-PACIFIC PARTNERSHIP. Foster, Rachel H.; Wilson, Nick // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/6/2011, Vol. 343 Issue 7818, p273 

    A letter to the editor is presented in response to the article on New Zealand's drug funding authority Pharmac and the Trans-Pacific Partnership trade agreement which is currently negotiated in the U.S., by R. Moynihan in the previous issue.

  • Andrew Schiermeier. Perry, Alex // Time International (South Pacific Edition);9/20/2010, Vol. 176 Issue 12, p34 

    The author reports on the involvement that the nonprofit organization Medicine in Need (MEND), under the leadership of chief executive officer (CEO) Andrew Schiermeier, has in the production of inexpensive drugs for the developing world.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics